Chronic granulomatous disease is a textbook target for gene therapy: a single faulty gene leaves white blood cells unable to produce the chemical burst they normally use to kill invading bacteria and fungi, so patients suffer repeated, sometimes life-threatening infections. The usual fix imagined for such diseases is permanent — edit or replace the gene in blood stem cells so the body makes corrected cells forever. A long-running National Institutes of Health trial that updated on the U.S. registry this week takes a strikingly different, more modest route: don't rewrite the genome at all, just hand the existing white blood cells a temporary instruction sheet.
The study, NCT05189925, is sponsored by the National Institute of Allergy and Infectious Diseases and is recruiting up to 25 adult men with X-linked CGD caused by a mutation in the gene for the gp91phox protein. The intervention, called gp91 Grans, uses the same molecular tool — messenger RNA — that powered the COVID-19 vaccines, but for an entirely different job. Here, the registry explains, the point is to deliver a correct copy of the gene's instructions into a patient's own cells.
"CGD is caused by a gene mutation. For people with CGD, their cells cannot kill germs well, so they can get frequent or life-threatening infections. Researchers want to see if a new procedure can help a person s cells kill germs for a short time. It uses messenger RNA (mRNA) to deliver correct instructions for the gene mutation to the cells."— ClinicalTrials.gov, source
Two words in that description carry the entire strategy: short time. Messenger RNA is inherently transient. A cell reads it, makes the protein it encodes, and then the message degrades. For a vaccine that is a feature — you want a brief protein production run, not a permanent one. For a disease like CGD, it is a deliberate trade-off. The approach cannot cure the patient, because the corrected cells are not stem cells and the mRNA does not last; what it can do, in principle, is give a person a window of functional germ-killing white blood cells — for instance, to help clear a serious active infection — without the risks that come with permanently altering the genome.
How the procedure works
The mechanics are involved, which is part of what this trial is testing. A participant first undergoes granulocyte-enriched apheresis: a medicine is given to mobilize their white blood cells, then blood is drawn through a machine that separates out the granulocytes and returns the rest. Those collected cells are transfected with the corrective mRNA outside the body and then infused back into the same patient. Because the cells and the genetic instructions are the patient's own, the immune-rejection concerns that complicate donor-cell approaches are sidestepped. The trial enrolls only patients without a systemic infection at the time of dosing, and it escalates the dose sequentially to find the most effective yet safe level.
What the endpoints actually test
The primary outcomes make clear this is a feasibility-and-safety study, not an efficacy trial. One endpoint is feasibility itself — whether the cells can be reliably recruited, manufactured, and infused. A second is determining the maximum tolerated dose, defined as the highest dose that does not cause the same grade 3 or 4 adverse events in three or more patients. A third tracks the frequency of grade 3 or greater adverse events related to the study agent. In other words, the questions are: can we make this product, how much can we safely give, and is the infusion tolerated? Whether it meaningfully helps patients fight infection is a downstream question this design is structured to enable, not to answer.
That restraint is the right read of the record. The single-arm, open-label, sequential dose-escalation design with up to 25 participants is built to establish the boundaries of a novel manufacturing-and-infusion procedure in a rare disease. The transient nature of the correction means even a fully successful trial would yield a temporary therapeutic tool rather than a one-time cure — a meaningful distinction for patients and physicians weighing options against the more permanent gene therapies in development for the same condition.
The feasibility endpoint is easy to overlook but central to what this trial is really testing. Granulocytes are short-lived cells — they circulate for hours to a day, not weeks — which means the entire manufacturing chain, from apheresis to mRNA transfection to reinfusion, has to be fast, reliable, and reproducible enough to deliver a viable product before the cells age out. That logistical bar is part of why feasibility sits as a co-equal primary outcome alongside the maximum tolerated dose and safety: a procedure that cannot be manufactured consistently is not a therapy, no matter how sound its biology. The sequential dose-escalation design, starting at the lowest level and stepping up only once a level is judged safe, is the conventional and conservative way to walk that line in a rare-disease population where each participant is precious and the product is bespoke. It also reflects the reality that a first-in-class autologous cell-and-mRNA procedure carries unknowns that no preclinical model fully predicts.
What makes NCT05189925 worth tracking is precisely that it occupies an underexplored middle ground. Most gene-therapy conversation is about permanence — edited stem cells, lifelong correction. This trial asks whether a deliberately temporary, mRNA-loaded autologous cell product can be manufactured safely and infused to buy a CGD patient a stretch of working immune cells. The honest takeaway today is that the study is testing feasibility, dose, and safety of that procedure in adult men with gp91phox-deficient CGD — and that any claim about how well it actually restores germ-killing in practice awaits the data this Phase 1 is designed to gather.